Journal article
Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12
Abstract
BACKGROUND: The NCIC CTG LY.12 study showed that gemcitabine, dexamethasone, and cisplatin (GDP) were noninferior to dexamethasone, cytarabine, and cisplatin (DHAP) in patients with relapsed or refractory aggressive histology lymphoma prior to autologous stem cell transplantation. We conducted an economic evaluation from the perspective of the Canadian public healthcare system based on trial data.
METHODS: The primary outcome was an incremental …
Authors
Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D
Journal
Journal of the National Cancer Institute, Vol. 107, No. 7,
Publisher
Oxford University Press (OUP)
Publication Date
July 1, 2015
DOI
10.1093/jnci/djv106
ISSN
0027-8874